^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMA201
i
Other names: IMA201, IMA-201, IMA201 T-Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immatics
Drug class:
TCR modulator, MAGE-A4 inhibitor, MAGE-A8 inhibitor
Related drugs:
4ms
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (clinicaltrials.gov)
P1, N=7, Completed, Immatics US, Inc. | Active, not recruiting --> Completed | N=22 --> 7 | Trial completion date: Dec 2024 --> Sep 2023
Trial completion • Enrollment change • Trial completion date • IO biomarker
|
cyclophosphamide • IMA201
3years
[VIRTUAL] First Anti-Tumor Activity Associated with Robust Biological Activity Observed in Early Phases of Dose Escalation Across Three TCR-T Trials (CIMT 2021)
Safety, biological activity and anti-tumoral efficacy are closely monitored throughout and following lymphodepletion with Fludarabine and Cyclophosphamide, T cell infusion and low dose IL-2 treatment. Taken together, treatment-emergent adverse events for ACTengine® product candidates were transient and manageable and in line with published data for autologous cell therapy in solid cancers. First anti-tumor activity in heavily pre-treated patients after infusion of low cell doses was unexpected, and together with robust biological activity warrants exploration of IMA201, IMA202 and IMA203 product candidates at target dose.
Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA1 (MAGE Family Member A1)
|
fludarabine IV • IMA201 • IMA202 • IMA203
Share via
